Check for updates

RESEARCH ARTICLE OPEN ACCESS

One-Stone-Three-Birds Biomimetic Oral Targeting Delivery Strategy for On-Demand Controlled Drug Release and Intervertebral Disc Degeneration Therapy

Yifan Ding[1] | Yixin Cai[1] | Weizhen Pan[2] | Na Hu[1] | Yunyun Wang[3] | Huan Wang[4,5] | Huang Fang[4] | Songwei Tan[2] | Zhiping Zhang[2]

[1]Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | [2]School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | [3]Department of Cardiology, Wuhan Fifth Hospital, Jianghan University, Wuhan, China | [4]Department of Orthopedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | [5]Department of Orthopedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Correspondence: Huang Fang (fanghuangtjh@hust.edu.cn) | Songwei Tan (tansongwei@gmail.com; tansw@hust.edu.cn)

Received: 11 February 2025 | **Revised:** 29 July 2025 | **Accepted:** 7 November 2025

Keywords: celastrol | intervertebral disc degeneration | oral targeted delivery | ROS-responsive | yeast microcapsule

ABSTRACT

Intervertebral disc degeneration (IDD) is a multifactorial condition characterized by excessive inflammation, immune dysfunction, and metabolic disorders. Current therapeutic strategies primarily rely on local injection, a traumatic approach associated with risks of tissue damage and infection. Therefore, developing safer, non-invasive, and precisely targeted drug delivery systems capable of multi-targeted interventions for the degenerating nucleus pulposus remains a significant challenge in IDD treatment. In this study, we designed a novel biomimetic oral delivery system featuring targeted drug delivery to degenerated intervertebral discs (IVDs) and on-demand drug release. This system utilizes yeast microcapsules (YC) and reactive oxygen species (ROS)-responsive nanoparticles to deliver Celastrol (Cel), a bioactive compound derived from traditional Chinese medicine. After oral administration, the system achieves targeted transport to IVDs through macrophage "hitchhiking," where the inflammatory microenvironment rich in ROS triggers accelerated Cel release. Importantly, this strategy embodies a "One-Stone-Three-Birds" therapeutic approach, simultaneously exerting multi-targeted biological effects: inhibiting inflammasome activation, reprogramming macrophage polarization, and modulating lipid metabolism. These synergistic actions reverse the adverse degenerative microenvironment of the nucleus pulposus, promote tissue regeneration, and effectively suppress the progression of IDD. This research presents a novel, non-invasive oral targeted delivery strategy for IDD treatment, integrating biomimetic engineering with on-demand drug release. This innovative approach offers a comprehensive framework for microenvironmental remodeling and provides new insights into intervertebral disc regeneration.

1 | Introduction

Lower back pain (LBP) affects over 600 million people globally, posing a substantial economic and healthcare burden [1]. Intervertebral disc degeneration (IDD) is the leading cause of LBP. The intervertebral disc (IVDs), the largest avascular structure in the human body, comprises the nucleus pulposus and annulus fibrosus, both rich in extracellular matrix (ECM) [2].

Yifan Ding, Yixin Cai, and Weizhen Pan contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Exploration* published by Henan University and John Wiley & Sons Australia, Ltd.

Degenerated discs exhibit vascular and neural ingrowth, accompanied by immune cell infiltration dominated by macrophages. This pathological process triggers inflammatory responses, oxidative stress, and disruptions in the immune microenvironment and metabolic homeostasis, ultimately disturbing ECM integrity and driving IDD progression [3–5].

In current clinical practice, IDD treatment primarily relies on pharmacotherapy and surgical interventions. Nonsteroidal anti-inflammatory drugs, the most common pharmacological option, provide symptomatic relief but fail to halt disease progression. Surgical approaches, although effective in alleviating pain in the short term, carry risks such as impaired spinal function and the potential to accelerate degeneration in adjacent discs [6]. These limitations underscore the urgent need for innovative, safer, and more effective therapeutic strategies for IDD.

Advances in nanomedicine and materials science have introduced new therapeutic avenues for IDD, particularly in localized sustained release and targeted drug delivery [7]. For example, Wenguo Cui developed hydrogel microspheres for IVDs injection that capture hydrogen ions and suppress inflammatory responses, achieving sustained anti-inflammatory effects [8]. Yue Wang designed an injectable hydrogel-extracellular vesicle system that delays aging of nucleus pulposus cells (NPCs) and ECM degradation [9]. Yuan Li developed a CXCL8-inhibiting biomimetic peptide (linoleic acid-mimicking) that attenuates IDD by protecting nucleus pulposus stem cells [10]. Liang Zhou et al. designed neutrophil membrane-coated nanoparticles targeting inflammatory NP tissue to suppress IDD [11]. Nguyen et al. reported an in situ IVDs injection of simvastatin-loaded nanodroplets, with controlled release triggered by high-intensity focused ultrasound [12]. Our group has also focused on developing targeted drug delivery systems for IDD, including passive targeting using liposomes and active targeting strategies employing ROS-responsive polymer nanoparticles for chemogene co-delivery to promote nucleus pulposus regeneration [13, 14]. Currently, localized injection remains the predominant drug delivery method in IDD research, but its invasive nature increases the risk of tissue injury and infection [15]. There is limited research on non-invasive drug delivery in the context of IDD. In one study, a fullerene-based nanocarrier capable of targeting macrophages was developed. Following tail vein injection in mice, the system effectively accumulated in degenerated discs, suppressing IDD-induced radicular pain [16]. In clinical settings, oral administration is favored for its superior safety and patient compliance. However, oral treatment of IDD faces challenges such as poor bioavailability, inefficient targeting, and short drug retention times, which significantly limit therapeutic efficacy [17].

Inspired by biomimetic principles, we focused on *Saccharomyces cerevisiae*-derived yeast capsules (YC) with demonstrated edible safety. After removing intracellular components, the obtained yeast microcapsules (YC) possess a unique hollow structure that enables efficient drug loading and controlled release, making them ideal drug delivery vehicles [18, 19]. Studies have confirmed that surface β-1,3-D-glucans on YC can be specifically recognized by macrophages through Dectin-1 receptors [20]. Capitalizing on the chemotactic properties of macrophages toward inflammatory sites, this system achieves precise drug delivery to distant pathological regions through the lymphatic and circulatory systems. Clinical and preclinical evidence consistently shows macrophage infiltration in degenerated intervertebral discs of both humans and rodents, with infiltration density positively correlating with degeneration severity [21–23].

Building on these insights, we propose a novel macrophage "hitchhiking" strategy for oral targeted IDD therapy. This approach employs yeast microcapsules (YC), which are internalized by macrophages following gastrointestinal exposure. Leveraging macrophage recruitment to degenerated IVDs, this system achieves non-invasive and oral-targeted drug delivery. Moreover, it regulates macrophage polarization and the degenerative microenvironment through an on-site, ROS-triggered drug release mechanism, representing a significant advancement in non-invasive IDD treatment strategies.

Traditional herbal medicine has long played a crucial role in disease management [24–27], particularly for chronic inflammatory conditions [28]. IDD is characterized by localized inflammation and oxidative stress, marked by the excessive release of pro-inflammatory cytokines and matrix metalloproteinases (MMPs) [29]. In this study, through virtual screening of over 20,000 natural small molecules, we identified Celastrol (Cel) from Tripterygium wilfordii, which exhibits high binding affinity to MMP13, a key enzyme in ECM degradation. Cel, similar to artemisinin in its broad spectrum of biological activities, is considered one of the most promising natural compounds for modern drug development [30]. Its anti-inflammatory, antioxidative, and immunomodulatory properties, including the neutralization of excessive ROS and reprogramming of macrophage polarization [31–33], position it as a compelling candidate for IDD therapy.

However, Cel's poor water solubility, low bioavailability, and rapid metabolism limit its clinical application. To address these challenges, we developed a ROS-responsive polymer, PBTEa (poly(β-thiodiester-β-amino ester)), featuring excellent biocompatibility and low cytotoxicity. PBTEa encapsulates Cel for controlled release, facilitated by ROS-responsive thioether bonds derived from dithiothreitol (DTT), ensuring targeted drug release in the oxidative environment of degenerated IVDs. Additionally, the incorporation of tertiary amine groups from 5-amino-1-pentanol (AP) imparts a positive surface charge, enhancing YC loading capacity. The polymer self-assembles into a core-shell structure, encapsulating Cel within its hydrophobic core to improve bioavailability and enable controlled drug release. The resulting Cel-PBTEa nanoparticles electrostatically complex with YCs, forming Cel-PBTEa@YC assemblies. Upon oral administration, these assemblies utilize macrophage "hitchhiking" to reach degenerated IVDs, where ROS-responsive release occurs at the target site.

Collectively, as illustrated in Figure 1, we have developed an innovative "One-Stone-Three-Birds" therapeutic strategy utilizing a novel biomimetic oral targeted delivery platform. This non-invasive approach demonstrates Cel's multifaceted therapeutic mechanisms in IDD management through three distinct pathways: (1) reprogramming macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, (2) suppressing NLRP3 inflammasome activation and downstream

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 1 | Schematic diagram of the preparation, delivery pathway, and therapeutic mechanism of the multifunctional ROS-responsive biomimetic oral targeting delivery platform (Cel-PBTEa@YC).

inflammatory cascades, and (3) restoring lipid metabolism homeostasis in NPCs. More importantly, this oral delivery system achieves on-demand drug release in response to the ROS-rich microenvironment of degenerated IVDs. Taken together, our study provides novel insights into targeted delivery and precision treatment strategies for IDD.

2 | Materials and Methods

2.1 | Reagents

Celastrol (Cel) was procured from APINNO Technology Co., Ltd., while 5-amino-1-pentanol (AP) and 1,4-butanediol diacrylate (BDD) were sourced from TCI (Shanghai, China). DTT was obtained from Aladdin (Shanghai, China). The solvents utilized in this study were of analytical grade and acquired from Sinopharm Group, China. Yeast microcapsules (YC) were procured from Lesaffre International Corporation, France. Interleukin-1 beta (IL-1β) and lipopolysaccharide (LPS) were respectively obtained from R&D Systems, Inc., and Beyotime Biotechnology Co., Ltd.

2.2 | Animals

Sprague–Dawley (SD) rats, weighing ranging from 210 to 230 g, were supplied by Hubei Biont Biological Technology Co., Ltd. All procedures involving animals adhered to the relevant Chinese laws and regulations and received authorization from the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology (HUST). The ethical approval for this research was granted under the number 2722.

2.3 | Synthesis of PBTEa Copolymer

BDD, DTT, and AP, in varying feed ratios as outlined in Table S1, Supporting Information, were co-dissolved in *N*, *N*-dimethylformamide (DMF) to achieve a total concentration of 1 mg mL^{-1}, under an ice bath. The mixture was stirred continuously for 6 h, after which the temperature was gradually increased to room temperature for an additional 6 h. Subsequently, the reaction continued at 70°C for 12 h. Following this, the solution was transferred into a dialysis tube (MWCO 2000) and dialyzed against a water/DMF mixture (50:50, v/v) twice, followed by pure water dialysis twice at 4°C, with the external phase refreshed every hour. The final product, PBTEa, was then obtained through lyophilization, ensuring a well-defined and pure polymeric material for subsequent applications.

2.4 | Preparation of YC, Cel-PBTEa, and Cel-PBTEa@YC

YC was prepared through a meticulous process where yeast contents were removed using a combination of acid, base, and organic solvent treatments. Initially, 20 g of yeast was mixed with 200 mL of 1 mol L^{-1} NaOH at 85°C for 1 h. Subsequently, the mixture was centrifuged to remove the supernatant and collect the precipitate. The pH of the collected precipitate was adjusted to 4–5 by adding a specified amount of concentrated hydrochloric acid (HCl) mixed with 200 mL of deionized water (dd-H_2O) and incubated at 65°C for 1 h. Post-incubation, the aggregation was separated via centrifugation and sequentially washed with dd-H_2O, isopropyl alcohol, acetone, and again with dd-H_2O. The final product, YC, was achieved by freeze-drying the thoroughly

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

washed precipitates, ensuring the integrity and purity of the YC for subsequent applications.

PBTEa (10 mg) and Cel (5 mg) were dissolved in 300 μL of dimethyl sulfoxide. Subsequently, this solution was aspirated using a 1 mL insulin syringe and incrementally added to 5 mL of phosphate-buffered saline (PBS), under continuous stirring with a magnetic stirrer for 15 min. The mixture was then transferred into a dialysis bag (3500 kDa molecular weight cut-off) to undergo dialysis, with the dialysis fluid being refreshed every 30 min, for a total of three exchanges. Following dialysis, the solution underwent freeze-drying, resulting in the formation of Cel-PBTEa nanoassemblies.

To ensure complete swelling of the YC suspension (10 mg mL^{-1}), intermittent vortexing for 5 min and ultrasonic dispersion for 5 min were employed. Following this, Cel-PBTEa in various ratios was incorporated into the suspension, which was then stirred at room temperature for 8 h. The resultant Cel-PBTEa@YC composite was finally obtained through freeze-drying, solidifying the integration of the nanoparticles with the YC to form a stable and functionalized nanoassembly for targeted therapeutic applications.

2.5 | ROS Analysis

To simulate the interaction between NPCs and macrophages in degenerated IVDs and the ROS-responsive release of the delivery system, the co-culture methodology was employed. Macrophages were cultured in Transwell chambers while NPCs were seeded in the bottom compartment. When cell confluence reached 80%, the culture was exposed to 100 μM H_2O_2 for 2 h to induce oxidative stress, simulating the inflammatory environment of degenerated discs. This was followed by a medium refresh and a 24-h treatment period using various formulations (Cel-PBTEa, Cel-PBAE@YC, and Cel-PBTEa@YC). Post-treatment, NPCs were treated with the DCFH-DA fluorescent marker and kept at 37°C for a duration of 30 min to assess ROS levels. After three washing steps, the cells were examined using a fluorescence microscope to visualize ROS generation. Additionally, NPCs were collected for flow cytometry analysis to quantitatively measure ROS levels.

To investigate the Cel release from macrophages after being uptaken. Cel was replaced with Coumarin-6 (C6) to prepare C6-PBTEa@YC. Raw 264.7 cells were seeded into six-well plates at a density of 5×10^5 cells per well and cultured overnight. Subsequently, the culture medium was replaced with a medium containing 200 ng mL^{-1} C6-PBTEa@YC (calculated based on C6). After 4 h of incubation, the supernatant was removed, and the cells were washed twice with PBS. Then, fresh culture medium, culture medium containing 50 μM H_2O_2, and culture medium containing 1 μg mL^{-1} LPS were added, respectively. After 4 h of incubation, the supernatants were collected, and the fluorescence intensity was measured using a fluorescence spectrophotometer.

In a parallel experiment focusing on the RAW 264.7 macrophage line, intracellular ROS production was evaluated using the DCFH-DA assay under different conditions. RAW 264.7 cells were grown in culture plates and subjected to treatment with LPS (200 ng mL^{-1}) to stimulate ROS production, providing a comparative insight into the ROS-responsiveness of the delivery systems in a macrophage-specific context.

2.6 | Toxicity In Vivo and In Vitro

Initially, the effects of small molecules LPS, IL1-β, and Cel on the morphology of NPCs and RAW 264.7 were observed under a bright-field microscope. Subsequently, the cell viability of NPCs and RAW 264.7 was assessed under various concentrations of nanoparticles through MTT and Calcein/PI staining. Upon determining the concentrations for cell intervention (Cel 50 ng mL^{-1}; LPS 200 ng mL^{-1}; and IL-1β 5 ng mL^{-1}), the proliferation and apoptosis effects on the aforementioned cells were examined using the EdU and TUNEL assay kits, respectively. Finally, the toxicity of these formulations on IVDs was evaluated through histological staining, and the impact of Cel-PBTEa@YC on the expression of key matrix metabolism proteins in the IVDs was investigated using tissue immunofluorescence techniques, with Abcam plc providing the antibodies. The other reagents mentioned above were acquired from Beyotime Biotechnology Co., Ltd. The above experiments were conducted according to the procedures provided by the manufacturers.

2.7 | Cellular Uptake

The study examined the engulfment of YC by macrophages and the internalization of YC and nanoparticles by NPCs. Initially, cells were cultured and left to attach for 24 h. After this period, they were exposed to either fluorescein isothiocyanate (FITC)-labeled YC (FITC-YC), FITC-labeled nanoparticles (FITC-PBTEa), or solely FITC and then analyzed using a fluorescent microscope. The absorption of these substances by the cells was later quantified using flow cytometry. This investigation detailed the cellular uptake in both RAW 264.7 cells and rat peritoneal macrophages (RPM).

2.8 | Bio-Distribution and Transport of Cel-PBTEa@YC

The in vivo localization of Cel-PBTEa@YC through oral delivery was investigated by indocyanine green (ICG), serving as a substitute for celastrol, loaded ICG-PBTEa@YC. Kunming mice were administered with ICG, ICG-PBTEa, and ICG-PBTEa@YC respectively, and then scanned at preset time points (0, 1, 3, 6, 12, 24, 36, and 48 h) using the near-infrared fluorescent imaging system (Pearl Trilogy, USA). After 48 h, the principal organs, lymph nodes (MLN: mesenteric lymph nodes; ALN: Axillary lymph nodes; ILN: Inguinal lymph nodes), and IVDs were removed for ex vivo fluorescence imaging to observe drug distribution in these tissues. In addition, the small intestine at 3 h was washed with physiological saline, followed by cryosectioning and staining of the nuclei with DAPI. The sections were then observed under a confocal microscope.

Meanwhile, we examined the mechanism behind the targeted bio-distribution to IVDs, using the Dectin-1 specific inhibitor, laminarin (LA), to investigate how macrophages recognize YC. After introducing LA, we observed the phagocytosis in both

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

RAW 264.7 and RPM through confocal microscopy and conducted quantitative analysis with flow cytometry.

2.9 | IDD Animal Model Establishment

The establishment of the IDD animal model utilizes a needling method in SD rats. In summary, sodium pentobarbital (2% (w/v), 50 mg kg^{-1}) is administered intraperitoneally for anesthesia. Subsequently, the level of Co8-9 (the 8th to 9th coccygeal vertebra) is identified through palpation and radiographic imaging. Needle puncture of 5 mm in the IVDs is performed using a 20-gauge needle, concurrently rotating the needle 360° twice to ensure successful establishment of the degenerated disc model.

To assess the therapeutic effect of Cel-PBTEa@YC on degenerative IVDs, experimental animals were allocated into six groups (n = 5, per group): Control, IDD, YC (70 mg kg^{-1}), Cel (3 mg kg^{-1}), Cel-PBTEa (3 mg kg^{-1}), and Cel-PBTEa@YC (3 mg kg^{-1}). The pharmaceutical formulations for the above groups were administered via gavage every 2 days. All animal procedures in this study complied with Hubei's regulations and Huazhong University of Science and Technology's ethical guidelines, with formal approval from the Institutional Animal Care and Use Committee (IACUC) at Tongji Medical College (IACUC Number: 2722).

2.10 | Imaging and Histological Animal Efficacy Assessment

The treatment mentioned above lasted for 8 weeks, with X-ray and magnetic resonance imaging (MRI) examinations at the time points of 0, 4, and 8 weeks. X-ray images were captured with distinct parameters: a 70 cm distance between collimator and film, an exposure level of 58 mA s, and a penetration capacity of 38 kV. MRI was conducted using the 1.5 T system from Siemens, Germany, to obtain T2-weighted images (repetition time, 3000 ms; echo time, 80 ms; field of view, 200 mm × 200 mm; and slice thickness, 2 mm). In the validation of RNA-Seq results, micro-computed tomography (micro-CT) scanning was performed on the rat IVDs using a micro-CT scanner (Scanco Medical, Switzerland). The parameters set for the CT scan were: voltage = 105 kV, current = 100 μA, and voxel size = 10 μm. Three-dimensional computed tomography (CT-3D) and X-ray images were acquired through the built-in assessment system of the micro-CT imaging system.

Post radiological examination, the IVDs were collected and fixed with 4% paraformaldehyde, followed by hematoxylin and eosin (HE), safranin O-fast green, and Alcian blue staining. Additionally, immunohistochemistry (IHC) and immunofluorescence (IF) staining were conducted in accordance with the manufacturer's instructions.

2.11 | Biosafety Evaluation

In the safety evaluation of Cel-PBTEa@YC, all the rats were sacrificed at the end of the experiment (8 weeks), and the heart, liver, spleen, lung, kidney, stomach, and intestines were excised for H&E and Giemsa staining. Blood extraction and centrifugation were conducted. The resultant plasma layer was tested for blood biochemical analysis.

2.12 | Statistical Analysis

Statistical analysis was conducted using GraphPad Prism version 9.0.0 software. For comparing two groups, the Student's t-test was utilized if the D'Agostino–Pearson normality test confirmed normal distribution within a significance level of 0.05. In cases where normality was not confirmed, the Mann–Whitney U test was selected for nonparametric data analysis. Analysis of three or more groups was performed using one-way ANOVA.

3 | Results and Discussion

3.1 | YC Fabrication and PBTEa Synthesis

Scanning electron microscopy revealed the yeast's elliptical appearance, with a surface covered by protruding buds of various sizes (Figure S1a,b, Supporting Information). After subjecting the yeast to acid-base and organic solvent treatments to remove its contents, YC with a cavity structure capable of loading contents were obtained (Figure 2a). We stained the yeast and YC with FITC, where the content-removed yeast displayed a hollow, capsule-like structure, albeit with residual contents that could be stained by FITC (Figure 2b; Figure S1d,e, Supporting Information). The use of Calcofluor White staining agent highlighted that β-1,3-glucan is primarily distributed on the cell wall of the yeast (Figure S1c, Supporting Information).

To incorporate a positively charged group into the ROS-responsive copolymer, we synthesized the PBTE-PBAE copolymer, designated as PBTEa, through Michael addition polymerization of BDD, DTT, and AP. Owing to the differential reaction rates between BDD-DTT and BDD-AP, the reaction commenced in an ice bath to prevent rapid polymerization of BDD-DTT. Subsequently, the temperature was elevated to 70°C to facilitate the reaction between AP and acrylic ester, leading to the formation of PBTEa (Figure S1f, Supporting Information). In the ^{1}H-NMR spectrum of PBTEa, characteristic peaks corresponding to BDD (4.12 ppm, —$OCOCH_2$), DTT (3.74 ppm, —$CH_2CH(OH)CH_2$), and AP (1.25–1.60 ppm, —$CH_2CH_2CH_2CH_2OH$; 3.58 ppm, —$CH_2CH_2CH_2CH_2OH$) units were identified, confirming the successful synthesis of PBTEa (Figure S1g, Supporting Information). The unit molar ratio in PBTEa, as deduced from the ^{1}H-NMR data, aligns with the initial feed ratio (Table S1, Supporting Information), indicative of the high reactivity characteristic of the Michael addition polymerization between acrylic ester and SH/OH groups. FT-IR results showed that $\upsilon_{C=O}$ at 1740 cm^{-1} in BDD, and υ_{C-S} at 660 cm^{-1} in DTT, and the broad peak (3200–3700 cm^{-1}) from the —OH group (in both AP and DTT) was identified. These results further confirmed the formation of PBTEa (Figure S1h, Supporting Information).

3.2 | Identification of Cel via Virtual Screening

MMPs, particularly MMP-13, play a pivotal role in IDD as the most potent collagenase responsible for extracellular matrix (ECM)

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 2 | Characterization and ROS responsiveness of Cel-PBTEa@YC. (a) TEM images of yeast and YC (scale = 2 μm). (b) Yeast fluorescence staining (scale = 2 μm). (c) TEM images of Cel-PBTEa@YC and its elemental analysis (scale = 5 μm). (d) Molecular structure of Cel and its binding overview with MMP13. (e) TEM images of PBTEa and Cel-PBTEa with or without H_2O_2 addition (scale = 500 nm). (f) Molecular dynamics simulation of the Cel-PBTEa complex system within 50 ns. (g) Changes in important parameters during the molecular dynamics simulation of Cel and PBTEa. (h) In vitro fluorescence imaging of PBTEa@YC loaded with ICG. (i) Fluorescence intensity statistics. *p* indicates statistical significance compared to the PBTEa group. (j) Release of Cel-PBTEa@YC in simulated gastrointestinal environment and its ROS-responsive behavior, $n = 3$.

degradation [34]. Notably, MMP-13 exhibits a collagenolytic activity five-fold higher than that of MMP-1, efficiently degrading type II collagen while also targeting other critical ECM components, including proteoglycans and type IV/IX collagen. Consequently, the direct inhibition of MMP-13 activity represents a promising therapeutic strategy to mitigate ECM catabolism and potentially halt IDD progression. The virtual screening identified MMP13 as the protein target. We first optimized the crystal structure of MMP13, defining its active site (Figure S2a, Supporting Information), and then conducted targeted small molecule screening in the CNPD database. Out of 13,462 small molecules, 12,104 were successfully docked. The molecules were then ranked based on their docking scores, with lower scores indicating stronger binding capabilities (Table S2, Supporting Information). The top 10 molecules, along with their docking scores and binding free energies, are listed. The top 3 small molecules identified were all bound at the designated active site (Figure S2b, Supporting Information). Further, this study analyzed the interaction details between MMP13 and the top 3 small molecules targeting it (Figure S2d, Supporting Information). From top 1 to top 3, it is evident that the small molecules targeting MMP13 primarily bind through hydrophobic interactions and hydrogen bonding. In top 1, a hydroxyl group of the small molecule forms a hydrogen bond with the amino group on THR224 of MMP13. The top 1 small molecule, identified as Celastrol (Cel) through comparison with structures in the CNPD database (Figure 2d), was found

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

to have a favorable targeted binding interaction with MMP13. Cel is sourced from the root bark of *Tripterygium wilfordii*, a plant belonging to the Celastraceae family. After confirming the effective binding interaction between Cel and MMP13, we further validated the biological effects of Cel binding to MMP13 through qPCR. It is shown that Cel can also significantly inhibit the upregulation of MMP13 and MMP3 expression induced by IL-1β in NPCs, and this inhibitory effect on MMP13 is dose-dependent (Figure S2c, Supporting Information). Furthermore, we evaluated the interaction between Cel and MMP13 using surface plasmon resonance (SPR). The results demonstrated that MMP13 binds to Cel in a concentration-dependent manner within the Cel concentration range of 20–10,000 nM (Figure S2e). Cel exhibited specific binding to MMP13 with an affinity of KD = 2.47 μM.

3.3 | Optimization and General Characterization of the Cel-PBTEa@YC Formulation

By setting different feed ratios of PBTEa, we first optimized the formulation of Cel-PBTEa nanoparticles, with the results indicating that the drug loading was highest at 23.53% ± 2.16% when the PBTEa to Cel ratio was 1:2 (Figure S4a, Supporting Information). Dynamic light scattering particle analyzer and TEM results were consistent, showing a decrease in particle size from 485.43 ± 16.91 to 353.09 ± 75.542 nm after the formation of nanoparticles (Figure S4d, Supporting Information), likely due to the compression of the nanoparticles resulting from the electrostatic interaction between the negatively charged carboxyl groups of Cel and the cationic polymer PBTEa, leading to a reduction in particle size.

Dynamic monitoring of the particle size changes of PBTEa and Cel-PBTEa nanoparticles revealed that within 48 h, their particle size fluctuations did not exceed 10% of their own particle size, indicating that these polymer self-assembled nanoparticles possess good stability (Figure S4d, Supporting Information). Zeta potential measurements showed that after conjugation with Cel, the positive charge value of PBTEa slightly decreased, but the overall complex remained positively charged. After the removal of contents to form YC, the absolute value of their negative charge decreased. When combined with the positively charged Cel-PBTEa nanoparticles, they still exhibited a negative potential, but the absolute value decreased, further illustrating that Cel-PBTEa and YC form the Cel-PBTEa@YC system through electrostatic interactions (Figure S4c,e, Supporting Information).

Furthermore, the self-assembly process of Cel and PBTEa in water was studied using Gromacs 2022.5. Two Cel molecules and five PBTEa molecules were placed in a water box system. Due to intermolecular interactions, the majority of the molecules aggregated after 50 ns (Figure 2f). We extended the simulation time to 100 ns and found that the system remained stable (Figure S3, Supporting Information). The radius of gyration (R_g) and the solvent-accessible surface area results showed that the system reached a stable state shortly after the simulation began (within 1 ns). In contrast, the root-mean-square deviation (RMSD) reached a stable state between 40 and 50 ns (Figure 2g). In summary, these results indicate that Cel and PBTEa can self-assemble into polymer nanoparticles in an aqueous medium.

Subsequently, based on the optimal formulation of Cel-PBTEa, we constructed a Cel-PBTEa@YC delivery system. The results showed that the highest drug loading of 6.46% ± 0.49% was achieved when the Cel-PBTEa to YC ratio was 1:1 (Figure S4b, Supporting Information). Concurrently, the presence of sulfur (S) elements in the system, originating from the thioether in PBTEa, was confirmed by elemental analysis using transmission electron microscopy (TEM), indicating successful loading of the Cel-PBTEa nano-complexes into YC (Figure 2c).

Additionally, we further investigated the stability of YC within RAW 264.7 over a period of 7 days. The DiI fluorescent dye clearly delineated the cell membrane boundaries of RAW 264.7, and the FITC-labeled YC were distinctly visible and intact within the macrophages. Throughout the 7-day dynamic observation period, the YC remained stable inside the macrophages without any structural disruption or disintegration (Figure S4f, Supporting Information).

After lyophilization, the YC samples stored for 4 and 8 weeks showed no Cel leakage, retaining their initial drug-loading efficiency (Figure S5a, Supporting Information), confirming long-term stability. Moreover, the morphology of drug-loaded YC remained essentially unchanged between 0 and 8 weeks (Figure S5b, Supporting Information). Further in vivo stability tests in simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, pH 6.8) demonstrated that YC maintained structural integrity for 24 h (Figure S5c, Supporting Information), indicating high gastrointestinal stability.

3.4 | ROS Responsiveness of Cel-PBTEa@YC

TEM results in Figure 2e show that PBTEa forms quasi-spherical structures with an average size of around 350 nm, exhibiting relatively uniform morphology. After encapsulating Cel, the size of PBTEa slightly decreased, which might be due to the electrostatic interaction between the positively charged PBTEa and negatively charged Cel, leading to a reduction in the nanoparticle size. Following H_2O_2 intervention, TEM results indicated nanoparticle disassembly, with aggregated nanoparticles becoming difficult to observe. This phenomenon could be attributed to the oxidation of thioether bonds in PBTEa to sulfoxide or sulfone under the influence of H_2O_2, significantly enhancing hydrophilicity and leading to the hydrolysis of ester bonds in the polymer chain (Figure S6, Supporting Information). ^{1}H-NMR analysis confirmed the ROS-responsive mechanism (Figure S7d, Supporting Information), with the DTT unit's characteristic peaks shifting downfield (a, b, c → a', b', c'-c''). The proton signal of -OH, likely affected by hydrogen bonding with S═O, shifted from 4.79 ppm to 5.46/5.40/5.34 ppm. Moreover, the —CH_2— proton signals near sulfur (d,e) in the BDD unit also moved downfield, indicating oxidation of thioether bonds to sulfoxide, which in turn accelerates hydrolysis of adjacent ester bonds. Additionally, a gradual clarification in color was observed in the gross appearance of PBTEa and Cel-PBTEa nanoparticles after H_2O_2 intervention (Figure S7e,f). Furthermore, fluorescence imaging revealed an incremental increase in fluorescence intensity post H_2O_2 intervention, suggesting the gradual release of the encapsulated fluorescent substance ICG from the material (Figure 2h,i). In vitro release studies of Cel-PBTEa@YC were

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

conducted by setting different pH values to simulate drug release in the gastrointestinal tract. Following H_2O_2 intervention in a neutral intestinal pH environment, a comparison with the Cel-PBAE@YC group lacking thioether bonds showed a significantly accelerated release of Cel, demonstrating the system's effective ROS responsiveness (Figure 2j).

Finally, we validated the ROS-responsive release of Cel-PBTEa@YC and its inhibition of ROS production in NPCs using a co-culture system. As shown in Figure S7a, RAW 264.7 cells were cultured in the upper layer and NPCs in the lower layer. After the intervention with H_2O_2 and the nanoparticle drug, ROS levels in the lower layer of NPCs were detected using the DCFH-DA assay kit. The results from fluorescence microscopy and flow cytometry quantitatively demonstrated that the Cel-PBTEa@YC system achieved ROS-responsive release and significantly inhibited ROS production in NPCs (Figure S7b,c). We also observed that Cel-PBTEa@YC can inhibit the increase in ROS levels in RAW264.7 induced by LPS (Figure S8a,b).

In summary, through experimental validation at both macroscopic and microscopic levels, we demonstrated that the sulfur ether bond-based Cel-PBTEa@YC delivery system possesses excellent inflammatory/ROS-responsive properties, precise targeted release, and effectively inhibits ROS production in NPCs by Cel.

3.5 | Toxicity Evaluation of Cel-PBTEa@YC

At the cellular level, we investigated the toxicity of Cel-PBTEa@YC on NPCs and RAW 264.7. Specifically, the inflammation model for NPCs was induced using IL-1β, while macrophages were stimulated with LPS to induce M1 polarization. After administering Cel to both cell types, no notable morphological alterations were observed when compared to the control group (Figure S8c). CCK-8 assay results indicated that the survival rates of NPCs and RAW 264.7 remained above 80% at a Cel concentration of 250 ng mL^{-1} (Figure 3a). Calcein-AM and propidium iodide (PI) staining demonstrated no significant necrosis (PI staining positive) in NPCs and RAW 264.7 under various drug formulations (Figure S8d). EdU assay for cell proliferation showed that neither Cel, Cel-PBTEa, nor Cel-PBTEa@YC significantly affected the proliferation of NPCs or RAW 264.7, not inhibiting their proliferation (Figure 3b; Figure S8e, Supporting Information). Furthermore, TUNEL staining confirmed that Cel-PBTEa@YC did not increase apoptosis in NPCs and RAW 264.7 (Figure S8f,g, Supporting Information).

Furthermore, we validated the safety of the delivery system at the level of IVDs tissue. After 8 weeks of oral administration in rats, IVDs sections were prepared and subjected to morphological and immunofluorescence (IF) staining. The results indicated that Cel-PBTEa@YC does not alter the morphology of IVDs tissues, indicating no local toxicity (Figure 3d). Additionally, at the protein expression level, IF results demonstrated that Cel-PBTEa@YC does not significantly affect the expression of key synthetic and degradative proteins in the IVDs (Figure 3c), further confirming the local safety of the delivery system.

16S rDNA sequencing of fecal samples (Figure S9) revealed that principal component analysis (PCA) (Figure S9a) manifested no significant separation between treatment and control groups, indicating minimal impact on microbial community structure. Assessment of alpha diversity through the Chao1 index (Figure S9b) revealed no significant differences in gut microbial diversity between the PBTEa@YC-treated group and control group, demonstrating that this oral delivery system does not adversely affect the ecological balance of intestinal microbiota. Further examination at the genus level (Figure S9c) demonstrated similar distribution patterns of predominant bacterial taxa. Phylogenetic cladogram analysis (Figure S9d) provided additional confirmation of microbial community stability between the PBTEa@YC-treated group and the control group. Together, these findings clearly show that extended PBTEa@YC administration maintains gut microbiota homeostasis without causing significant ecological disturbances

3.6 | Uptake of YC and Yeast by RAW 264.7 and RPM Cells

We investigated the uptake of YC and yeast by the macrophage cell line RAW 264.7 and RPM. The fluorescence microscopy and flow cytometry results demonstrated that both RAW 264.7 and RPM significantly internalize YC and yeast, with the uptake increasing over a time gradient (Figure 3e,f; Figure S10a,b,d,e, Supporting Information). Additionally, we explored the uptake of this delivery system by NPCs, noting that they effectively internalize both the free drug and the drug-nanoparticle system, with uptake increasing over a 4-h time gradient (Figure 3g,h; Figure S10f-g, Supporting Information). However, NPCs were unable to internalize YC, neither at the initial 0.5 h nor when the uptake duration was extended to 4 h (Figure S10c, Supporting Information). The limited uptake of YC by NPCs may be related to the larger diameter of YC, as these cells show better uptake efficiency for nanoparticles with diameters below 800 nm. However, this does not affect the in vivo functionality of the delivery system. The Cel contained within the YC ultimately exerts its effects in the form of free drug or drug-nanoparticle complexes, with the YC serving solely as a medium for targeted delivery.

3.7 | Bio-Distribution and Transport of Cel-PBTEa@YC

After confirming that Cel-PBTEa@YC could be taken up by macrophages, we further investigated its distribution and transport in animals via oral administration. Near-infrared fluorescence in vivo imaging system showed that it had good targeting ability to the IVDs. At 48 h, there was no fluorescence distribution in the IVDs in both the ICG group and the ICG-PBTEa group, while the ICG-PBTEa@YC group showed significant enrichment in the IVDs (Figure 4a), indicating the good targeting capability of the YC delivery system. After 48 h, we extracted the main organs, gastrointestinal tract, and IVDs tissues from the animals and conducted ex vivo fluorescence imaging on these tissues. We found that the IVDs in the ICG-PBTEa@YC group showed significant fluorescence accumulation, and the fluorescence intensity in the gastrointestinal tract and lymph nodes was markedly higher than that in other control groups (Figure 4b,c). We further investigated

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 3 | Toxicity and uptake investigations of Cel-PBTEa@YC. (a) CCK-8 assay for NPCs viability, $n = 3$. (b) EdU proliferation assay for RAW 264.7 (scale = 100 μm). (c) IF of key anabolic and catabolic proteins in the IVDs (scale = 500 μm). (d) Histological staining of IVDs in SD rats (scale = 500 μm). (e) Uptake of YC by RAW 264.7 (scale = 10 μm). (f) Flow cytometric quantification of uptake by RAW 264.7. (g) Uptake of FITC-PBTEa by NPCs (scale = 100 μm). (h) Flow cytometric quantification of FITC-PBTEa uptake by NPCs.

the intestinal transport of ICG-PBTEa@YC. In the free ICG group, fluorescence signals were dispersed around the nuclei of intestinal villus cells, indicating passive diffusion. In contrast, the ICG-PBTEa@YC group exhibited aggregated fluorescence signals on the basal side of the small intestine, with minimal signals near villus cell nuclei, suggesting a transport pathway potentially mediated by Peyer's patches (Figure S11a, Supporting Information). These findings support the proposed oral delivery route: gastrointestinal tract → Peyer's patches → lymph nodes → IVDs.

We also explored the recognition mechanism between YC and macrophages. By employing laminarin (LA), a specific inhibitor targeting the Dectin-1 receptor, we observed a notable suppression in the macrophage's uptake of YC. Moreover, the degree of inhibition was directly proportional to the concentration of LA (Figure 4d–f; Figure S10h,i, Supporting Information). This finding is in alignment with results reported in prior literature [20].

Having demonstrated that the oral delivery system accumulated in Peyer's patches, we next explored how targeted release could be achieved in IVDs. To investigate the release mechanism at the cellular level, we employed Coumarin-6 (C6)-labeled PBTEa@YC (C6-PBTEa@YC) as a fluorescent model in Raw 264.7 cells. Following cellular uptake, H_2O_2 or LPS stimulation for 4 h significantly increased fluorescence intensity in the culture medium compared to the control, demonstrating ROS- and

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 4 | In vivo distribution of Cel-PBTEa@YC and investigation into the YC-macrophage recognition mechanism. (a) In vivo fluorescence imaging, $n = 3$. (b) Ex vivo fluorescence imaging of major organs. (c) Ex vivo fluorescence imaging of major lymph nodes and IVDs (MLN: mesenteric lymph node; ALN: axillary lymph node; ILN: inguinal lymph node). (d,e) Fluorescence staining of macrophage uptake of YC (scale = 25 μm). (f) Relative quantification of fluorescence. *p* indicates statistical significance compared to the YC group.

inflammation-triggered release. In the absence of stimuli, fluorescence intensity remained stable, indicating minimal spontaneous release under normal conditions (Figure S11b, Supporting Information). These results confirm the system's on-demand release capability, maintaining stability under physiological conditions while achieving responsive release in inflammatory or oxidative environments in IVDs.

3.8 | Radiological Evaluation of In Vivo Therapeutic Efficacy

After administering the YC oral delivery system to the experimental animals for 4 and 8 weeks, they were subjected to radiological examination (X-ray and MRI) and histological section analysis (Figure 5a). The results indicated that in the IDD group, the

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 5 | In vivo therapeutic efficacy evaluation of the oral YC delivery system. (a) Animal experimental protocol. (b) Pfirrmann grading, %DHI change, and histological scoring. *p* indicates statistical significance compared to the IDD group. (c,d) MRI assessment of IDD treatment. (e) X-ray assessment of therapeutic efficacy in animals. (f,g,h) H&E, safranin O-fast green, and Alcian blue staining of IVDs (scale = 500 μm).

T2 signal of the IVDs significantly decreased at 4 weeks, and the disc height index (DHI) was substantially reduced compared to the sham group. The YC group showed similar parameters to the IDD group with no significant difference, indicating that the empty YC had no apparent therapeutic effect on IDD. The treatment groups (Cel, Cel-PBTEa, and Cel-PBTEa@YC) inhibited the decrease in T2 signal and reduction in DHI to varying extents. By the 8th week, the DHI% was 1.18, 1.46, and 1.98 times that of the IDD group, respectively, with Cel-PBTEa@YC showing the most significant treatment effect (Figure 5b–e). This effect was markedly distinct compared to other treatment groups, further validating the experimental hypothesis at the animal level. It suggests that Cel delivered to the IVDs via the YC system plays a role in inhibiting IDD, whereas other treatment groups lacking this delivery system do not achieve drug enrichment in degenerated discs, resulting in limited therapeutic effects in animal experiments.

3.9 | Histological Evaluation of In Vivo Therapeutic Efficacy

Following imaging assessments, the animals' IVDs were processed for fixation, decalcification, and histological staining (H&E, safranin O-fast green, Alcian blue) to examine their histological structure. Compared to the sham group, the IDD

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

group displayed a significant reduction in NPCs and disruption of the annulus fibrosus layers at weeks 2 and 4. The Cel-PBTEa@YC group, in contrast to the IDD group, preserved the normal morphology of NPCs and annulus fibrosus cells (Figure 5f–h). After 8 weeks of treatment, the histological scores of the IVDs in the Cel, Cel-PBTEa, and Cel-PBTEa@YC groups decreased by 30%, 35%, and 55%, demonstrating Cel-PBTEa@YC's superior therapeutic efficacy (Figure 5b).

Immunohistochemistry (IHC) results indicated that Cel-PBTEa@YC can regulate the metabolic balance of IVDs, restoring the expression of the nucleus pulposus matrix protein, type II collagen (Col2a1), while inhibiting the overproduction of the inflammasome (NLRP3) and MMP13 in the IVDs (Figure S12a, Supporting Information). IF results indicated that TLR2 was highly expressed in the degenerated IVDs induced by needle puncture. The Cel-PBTEa@YC treatment group suppressed its expression, highlighting its anti-inflammatory effects in vivo (Figure S12b, Supporting Information).

3.10 | System Safety Evaluation of Cel-PBTEa@YC

To evaluate the biosafety of Cel-PBTEa@YC, SD rats were orally administered YC, Cel, Cel-PBTEa, and Cel-PBTEa@YC for 8 weeks. Subsequently, their major organs and gastrointestinal tissues were examined using H&E and Giemsa staining (Figure S13, Supporting Information). No significant histological damage or pathological changes were observed in the treatment groups, consistent with the sham group. Furthermore, venous blood from the SD rats was collected to conduct blood biochemistry, complete blood count, and measurements of blood glucose and lipids. The biochemistry tests included alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN); complete blood count tests included red blood cells (RBC), white blood cells (WBC), hemoglobin concentration (HGB), and platelet count (PLT); lipid tests included triglycerides (TG), cholesterol (CHO), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). The results for all these parameters were within normal ranges (Figure S14, Supporting Information). Therefore, this oral delivery system demonstrates good biosafety and does not induce significant systemic adverse reactions.

3.11 | Transcriptome Sequencing Reveals Cel Inhibits IDD via TLR2/MyD88/P65/NLRP3 Axis

Transcriptome high-throughput sequencing analysis was employed to explore the mechanism by which Cel affects NPCs regeneration (Figure 6a). Principal component analysis (PCA) results demonstrated the intra-group similarity and inter-group differences among the three groups (Figure S15a, Supporting Information), with heatmaps of overall differential gene expression further confirming these similarities and differences (Figure S15b, Supporting Information). Furthermore, the correlation analysis shows that the Pearson correlation coefficients within each group all exceed 0.99, demonstrating good intra-group reproducibility (Figure S15i, Supporting Information). Following induction with IL-1β, compared to the PBS group, 1769 differentially expressed genes were identified, including 1081 upregulated and 688 downregulated genes. After IL-1β-induced inflammation in NPCs, Cel intervention identified 756 differentially expressed genes, with 315 upregulated and 441 downregulated (Figure 6b). Transcriptome sequencing results showed that IL-1β induction led to matrix protein degradation in NPCs and increased expression of catabolic genes, whereas Cel intervention inhibited catabolism, mitigating the loss of ECM components in NPCs (Figure 6e). This was further validated by qPCR, which confirmed the gene expression related to synthesis, catabolism, and inflammation (Figure 6o). KEGG pathway enrichment analysis and gene set enrichment analysis (GSEA) manifested significant suppression of pathways closely related to inflammation (Toll-like receptor pathway, NF-κB pathway, NOD-like receptor pathway) (Figure 6c,e,f), with similar results in the IL-1β_vs_PBS group (Figure S15c–f, Supporting Information).

TLR2, a key component of the Toll-like receptor pathway, was predicted to interact closely with MyD88 in the STRING database (Figure 6g). Laser confocal fluorescence microscopy revealed colocalization of TLR2 and MyD88 following IL-1β induction (Figure S15g,h, Supporting Information). Thus, it is plausible to infer that Cel promotes nucleus pulposus regeneration by inhibiting the inflammatory response in NPCs via the TLR2/MyD88/P65/NLRP3 pathway. We validated through co-immunoprecipitation (Co-IP) experiments that the interaction between TLR2 and MyD88 is enhanced following IL-1β induction, and Cel can attenuate this protein interaction (Figure 6h). After employing TLR2 specific inhibitor C29, the loss of normal phenotype in NPCs induced by IL-1β at the cellular level, and the loss of IVDs height due to degeneration at the animal level, were partially reversed (Figure 6i,m; Figure S16a,b, Supporting Information), with a clear inhibition of the TLR2/MyD88/P65/NLRP3 pathway (Figure 6j; Figure S16c, Supporting Information). TFA (TLR2 pathway activator) activated the TLR2/MyD88/NF-κB p65/NLRP3 pathway, while Cel significantly inhibited this activation compared to TFA, confirming its pathway suppression effect (Figure S16d,e, Supporting Information). The key protein in this pathway is the NF-κB effector protein P65, whose phosphorylation is enhanced under IL-1β induction, while C29 and Cel inhibited this phosphorylation (Figure 6l; Figure S16f, Supporting Information), thereby suppressing the activation of the inflammasome pathway and promoting the expression of matrix proteins Col2a1 and Aggrecan (Acan) (Figure 6k,n; Figure S16g, Supporting Information). In summary, through transcriptome sequencing and experimental validation, we demonstrated that Cel can promote synthetic metabolism and inhibit catabolic metabolism in NPCs, and this effect is mediated through the TLR2/MyD88/P65/NLRP3 pathway.

3.12 | Metabolomics Sequencing Reveals Cel Inhibits IDD Through Lipid Metabolism Reprogramming

Inflammation is closely linked to lipid metabolism, with studies indicating that inflammation can promote lipid metabolic disorders [35–37]. Our deeper exploration of the transcriptome sequencing data revealed that Cel's intervention is closely related to lipid metabolism and the pentose phosphate pathway by GSEA (Figure 7c). Subsequent non-targeted metabolomics sequencing further explored Cel's regulatory effects on NPCs. The PCA

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 6 | Transcriptome sequencing reveals that Cel inhibits IDD via the TLR2/MyD88/P65/NLRP3 pathway. (a) RNA-Seq workflow. (b) Volcano plot of differential gene expression in IL-1β+Cel_vs_IL-1β group and (c) KEGG enrichment analysis. (d) Illustrative diagram depicting the proposed mechanism of Cel inhibiting IDD. (e) Heatmap depicting the gene expressions of phenotypic profiles and inflammation pathways in NPCs. (f) GSEA for inflammation pathways in IL-1β+Cel_vs_IL-1β group. (g) STRING database prediction of TLR2 interacting proteins. (h) Co-immunoprecipitation (Co-IP) of TLR2 with MyD88. (i,j) Protein expression levels of the TLR2/MyD88/P65/NLRP3 axis after treatment with Cel and C29. (k) Cel promotes the upregulation of ECM components in NPCs. (l) Effect of Cel on p-P65 expression in NPCs (scale = 100 μm). (m) Inhibition of IDD by Cel and C29 at the animal level (scale = 2 mm). (n) Effect of Cel on Col2a1 expression in NPCs (scale = 100 μm). (o) qPCR validation of NPCs phenotype-related genes based on RNA-Seq results. *p* indicates statistical significance compared to the IL-1β group.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 7 | Untargeted metabolomic sequencing reveals that Cel inhibits IDD through reprogramming of lipid metabolism. (a) Schematic diagram of differential metabolites involved in energy and substance metabolism in NPCs. (b) Firework plot of differential metabolites involved in ECM metabolism. (c) GSEA results related to lipid and carbohydrate metabolism from RNA-Seq of IL-1β+Cel_vs_IL-1β group. (d) Differential metabolites in Cel+IL-1β_vs_IL-1β group. (e) Violin plot of typical differential metabolites (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$, $n = 4$, red arrows indicate upregulation, blue arrows indicate downregulation).

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

revealed distinct metabolic profiles across the three groups, demonstrating the intervention's notable effect on the metabolic patterns of NPCs and confirming the samples' high repeatability (Figure S17a, Supporting Information). The decrease in α-D-galactose-1,3-β-D-galactose-1,4-*N*-acetyl-D-glucosamine (Gal-GlcNAc), a vital ECM component, suggests IL-1β-promoted ECM degradation (Figure S17b, Supporting Information). Correlation analysis of differential metabolites post-IL-1β intervention identified amino acid synthesis and lipid metabolism as central nodes (Figure S17c, Supporting Information). Following Cel intervention, the bubble chart of differential metabolites showed a notable increase in Gal-GlcNAc (Figure S17d, Supporting Information), which has a high mass-to-charge ratio due to its large molecular weight. The Venn diagram analysis identified 42 differential metabolites from the two interventions (Figure S17e, Supporting Information), and KEGG pathway analysis connected these metabolites to amino acid metabolism, lipid metabolism, oxidative stress, and the TCA cycle, suggesting Cel's involvement in substrate and energy metabolism processes of NPCs (Figure S17f,g, Supporting Information).

After Cel treatment in IL1-β stimulated NPCs, the firework diagram generated from Reactome Database shows differential metabolite enrichment in various biological processes such as signal transduction and cell cycle response (Figure S17h, Supporting Information). A focused analysis reveals these metabolites are significantly involved in fatty acid and ECM metabolism (Figure 7b), suggesting Cel might influence ECM metabolism through fatty acid pathways, potentially modulating the process of IDD.

We constructed heatmaps of differential metabolites for two intervention groups (Cel+IL-1β_vs_IL-1β and IL-1β_vs_PBS) to investigate Cel's impact on NPCs at the single metabolite level (Figure 7d,e; Figure S18, Supporting Information). Following IL-1β treatment, citrate levels rose while ribose 1,5-bisphosphate decreased, suggesting TCA cycle activation and pentose phosphate pathway suppression during inflammation. Cel's intervention then lowered TCA cycle intermediates citrate and succinate, diminishing TCA activity but enhancing the pentose phosphate pathway. In its physiological state, nucleus pulposus tissue exists in a closed, hypoxic microenvironment, relying primarily on glycolysis for energy metabolism. Cel's intervention, by reducing TCA cycle levels, may boost glycolysis and the pentose phosphate pathway, enhancing energy utilization and biosynthetic metabolism in NPCs within an inflammatory environment. Perhaps the depth of metabolomic analysis was inadequate, resulting in no detected changes in glycolysis-related metrics.

In the aminoglycoside metabolic pathway, metabolites such as D-Mannose, GDP-L-Fucose, and Gal-GlcNAc exhibit similar trends. In the IL-1β group, their metabolite concentrations significantly decrease, with the average concentration of Gal-GlcNAc being only 0.014 times that of the PBS group. After Cel intervention, the metabolite concentrations are restored, with the concentration of Gal-GlcNAc in the Cel intervention group being 28.45 times that of the IL-1β group ($p = 1.88 \times 10^{-7}$, VIP = 1.74). D-Mannose and GDP-L-Fucose provide the carbon chain skeleton for proteoglycan synthesis, while Gal-GlcNAc, a type of proteoglycan, is a crucial component of the ECM. These results indicate that Cel significantly promotes the production of these metabolites, providing ECM for nucleus pulposus regeneration.

Prostaglandin A2 (PGA2), synthesized from arachidonic acid via cyclooxygenase, enhances IDD progression by promoting inflammatory factors release [38, 39]. Post-IL-1β treatment, PGA2 levels increase in NPCs but significantly decrease following Cel intervention. This indicates Cel's potential in inhibiting PGA2 synthesis, thus reducing inflammation and aiding nucleus pulposus regeneration. LC-MS/MS analysis revealed that IL-1β stimulation elevated PGA2 levels from 22.0 to 262.4 ng mL^{-1}, whereas Cel treatment significantly reduced it to 152.1 ng mL^{-1} (Figure S19, Supporting Information), confirming its anti-inflammatory metabolite-modulating effect. Prostaglandin J2 (15-Deoxy-d-12,14-PGJ2, PGJ2), the first identified endogenous ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ), dose-dependently activates PPAR-γ to curb inflammation [40]. Cel mitigates IL-1β-induced PGJ2 reduction, suggesting Cel's role in promoting PGJ2 production to suppress inflammation in NPCs.

Palmitic acid, known for activating the NLRP3 inflammasome and triggering inflammation [41], significantly varies before and after interventions. Specifically, in the IL-1β group, its levels are 7.80 times higher than in the PBS group. Post-Cel treatment, this level drops to 0.35 times that of the IL-1β group, suggesting Cel's potential in reducing palmitic acid levels and mitigating IDD.

In summary, as depicted in Figure 7a, NPCs undergo a metabolic shift during IDD, characterized by increased TCA cycle activity and reduced pentose phosphate pathway levels. After 48 h of Cel intervention in NPCs, there's an enhancement at the pentose phosphate pathway levels, providing reductants for amino sugar and fatty acid metabolism. The generated NADPH helps combat intracellular oxidative stress and maintains homeostasis. Cel directly stimulates the synthesis of glycosaminoglycans and precisely regulates lipid metabolism, producing anti-inflammatory effects. This includes downregulating inflammatory molecules and MMPs, fostering nucleus pulposus regeneration.

3.13 | Cel-PBTEa@YC Attenuates IDD by Regulating Macrophage Polarization

Macrophages play a crucial role in IDD, where M1 polarization typically promotes inflammation while M2 polarization is associated with inflammation suppression [42]. Predominantly, M1 macrophages are localized in degenerated IVDs, enhancing inflammatory responses and accelerating IDD. In this study, Cel-PBTEa@YC targets macrophages for oral delivery to IVDs, where Cel-PBTEa are released in response to high local ROS levels. In vitro experiments demonstrated that Cel inhibited LPS-induced M1 macrophage polarization and promoted a shift toward M2 polarization, indicated by reduced CD86 (M1 marker) expression and increased CD206 (M2 marker) expression (Figure 8b). Additionally, qPCR and Western blotting (WB) confirmed that this delivery system boosted M2 marker expression (CD206, IL-10) and suppressed M1 marker expression (CD86, COX-2, TNF-a, IL-6, iNOS) (Figure 8c,d). Flow cytometry analysis corroborates these findings (Figure 8f).

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




FIGURE 8 | Cel inhibits IDD by reprogramming macrophage polarization. (a) The mechanism diagram: Cel inhibits IDD by suppressing M1 macrophage polarization and promoting M2 polarization. (b) IF result reveals that Cel inhibits LPS-induced M1 macrophage polarization and promotes M2 polarization (scale = 50 μm). (c) Expression of inflammatory cytokines related to M1 macrophages. (d) Effect of Cel on gene expression related to LPS-induced M1 macrophage polarization. *p* indicates statistical significance compared to the LPS group, $n = 3$. (e) IF result for the M2 macrophage surface marker CD206, (scale = 50 μm). (f) Flow cytometry results showing that Cel-PBTEa@YC inhibits M1 macrophage polarization. (g) Effect of Cel on gene expression related to IL-4-induced M2 macrophage polarization, *p* indicates statistical significance, $n = 3$. h) Flow cytometry results showing that Cel-PBTEa@YC promotes M2 macrophage polarization. (i) IHC result showing Cel-PBTEa@YC promotes M2 polarization and inhibits M1 polarization of macrophages in the IVDs (scale = 100 μm).

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

In vivo animal experiments demonstrated that after 8 weeks of treatment in rats, IHC staining of macrophage surface markers showed that Cel-PBTEa@YC effectively inhibits CD86 expression more significantly than the Cel group and Cel-PBTEa group, while simultaneously promoting CD206 expression (Figure 8i). Arginase-1 (Arg-1), usually associated with inhibiting inflammation, is an M2 macrophage secretory product, whereas inducible nitric oxide synthase (iNOS) promotes inflammatory responses. IF staining of the IVDs revealed that Cel-PBTEa@YC enhances Arg-1 expression and reduces iNOS levels, aiding nucleus pulposus regeneration (Figure S20b, Supporting Information). Moreover, with IL-4 induced macrophage toward M2 polarization, the Cel-PBTEa@YC delivery system maintained the M2 macrophage phenotype, evidenced by increased expression of M2 markers (CD206, CD163, Arg-1, IL-10) compared to the control group by IF, qPCR, and flow cytometry analysis (Figure 8e,g,h). Further investigation into the PI3K/AKT/mTOR pathway, which is activated by LPS and implicated in macrophage polarization [43, 44], revealed that Cel-PBTEa@YC decreases the phosphorylation of PI3K/AKT/mTOR, inhibiting pathway activation (Figure S20a, Supporting Information). This suggests that the modulation of macrophage polarization by Cel-PBTEa@YC might be related to the suppression of PI3K/AKT/mTOR pathway activation. Additionally, the macrophages' migration ability, assessed before and after phagocytosis of Cel-PBTEa@YC through scratch assays and crystal violet staining, was not impaired, maintaining their normal migratory function essential for inflammation response and targeted delivery to the IVDs (Figure S20c,d, Supporting Information). In summary, this oral drug delivery system, utilizing macrophage "hitchhiking" for targeted delivery to the IVDs, reprograms their polarization toward M2, reducing inflammation and facilitating nucleus pulposus regeneration (Figure 8a).

The proposed "one-stone-three-birds" therapeutic strategy is well demonstrated by the experimental results. By modulating the critical process of macrophage polarization, the Cel-PBTEa@YC delivery system achieves synergistic effects of anti-inflammation, immune regulation, and metabolic reprogramming. Experimental data show that this system not only significantly upregulates M2 markers (Arg-1, CD206, etc.) but also effectively inhibits the production of pro-inflammatory mediator iNOS. This bidirectional regulatory effect suggests its sequential action of "first modulating the inflammatory microenvironment, then remodeling immune homeostasis." These changes in inflammation and immune regulation ultimately reshape cellular metabolism, thereby halting IDD progression. Such sequential therapeutic effects disrupt the "inflammation-immune-metabolism" vicious cycle in degenerated discs.

However, this chronological mechanism requires further experimental validation, including time-course measurements of inflammatory factors, immune cell phenotypes, and metabolic intermediates; spatiotemporal transcriptomic analysis; and dynamic metabolic flux assays. These studies will verify our proposed mechanism and represent key directions for future research.

Our study has several limitations that need to be addressed in future research. First, the in vivo distribution of the YC oral delivery system was only assessed via live imaging, and further pharmacokinetic studies, including oral bioavailability and ADME (absorption, distribution, metabolism, and excretion) profiling, are required to optimize its therapeutic potential. Second, the puncture-induced IDD model represents acute injury rather than the chronic, multifactorial degeneration seen in clinical settings; thus, more physiologically relevant models (e.g., mechanical loading or aging-associated models) should be developed. Third, while Cel-PBTEa@YC showed promising efficacy in SD rats, large-animal studies (e.g., pigs or non-human primates) and long-term safety evaluations are necessary to better predict clinical outcomes. Fourth, the proposed TLR2/MyD88/NF-kB/NLRP3 axis, though mechanistically sound, lacks novelty; multi-omics approaches (e.g., transcriptomics/proteomics) could uncover novel therapeutic targets. Last, translational challenges-such as scalable production, cost-effectiveness, and regulatory compliance-must be addressed to facilitate clinical adoption. Future work should integrate these aspects to advance Cel-PBTEa@YC toward real-world applications.

4 | Conclusion

This study presents, for the first time, an innovative multifunctional oral targeted drug delivery system with ROS-responsive on-demand release behavior for IDD treatment. The Cel-PBTEa@YC system integrates three synergistic therapeutic functions: (1) reprogramming pro-inflammatory M1 macrophages to anti-inflammatory M2 phenotypes, (2) inhibiting the TLR2/MyD88/p65/NLRP3 signaling pathway, and (3) restoring lipid metabolism homeostasis. Leveraging the "One-Stone-Three-Birds" strategy, this system is efficiently transported to degenerative IVDs via macrophage "hitchhiking" and releases Cel in response to the inflammatory microenvironment. By modulating the imbalanced microenvironment in IVDs and promoting nucleus pulposus regeneration, this system offers a novel, safe, and promising approach for the oral targeted therapy of IDD.

Author Contributions

Yifan Ding, Yixin Cai, and Weizhen Pan contributed equally to this work. Yifan Ding and Yixin Cai performed the experiments and data analysis. Weizhen Pan assisted with experimental design and data interpretation. Na Hu and Yunyun Wang participated in methodology and validation. Huan Wang contributed to formal analysis and data curation. Huang Fang and Songwei Tan conceptualized this work, supervised the research, provided funding, managed project and reviewed the manuscript. Zhiping Zhang contributed to conceptualization and project administration. All authors reviewed and approved the final manuscript.

Acknowledgments

The authors thank the support of the National Natural Science Foundation of China (Nos. 81271347 and 81871473) and Wuhan Knowledge Innovation Dawn Project (No. 2022020801020376). The authors also acknowledge the assistance provided by the Experimental Medicine Research Center of Tongji Hospital. The authors thank the Analytical and Testing Centre of HUST for TEM measurements. They also thank the Medical Sub-center of Analytical and Testing Center of HUST for their support in conducting ^{1}H-NMR. Additionally, the authors grateful acknowledge the Laboratory Animal Center of HUST for providing animal housing facilities.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Conflicts of Interest

The authors declare no conflicts of interest.

Ethics Statement

All procedures involving animals adhered to the relevant Chinese laws and regulations and received authorization from the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology (HUST). The ethical approval for this research was granted under the number 2722.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. GBD 2021 Other Musculoskeletal Disorders Collaborators, "Global, Regional, and National Burden of Other Musculoskeletal Disorders, 1990–2020, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021," *Lancet Rheumatology* 5, no. 11 (2023): e670–e682, https://doi.org/10.1016/S2665-9913(23)00232-1.

2. E. E. McDonnell, N. Wilson, M. N. Barcellona, et al., "Preclinical to Clinical Translation for Intervertebral Disc Repair: Effects of Species-Specific Scale, Metabolism, and Matrix Synthesis Rates on Cell-Based Regeneration," *JOR Spine* 6, no. 3 (2023): e1279, https://doi.org/10.1002/jsp2.1279.

3. R. Jha, J. D. Bernstock, J. I. Chalif, et al., "Updates on Pathophysiology of Discogenic Back Pain," *Journal of Clinical Medicine* 12, no. 21 (2023): 6907, https://doi.org/10.3390/jcm12216907.

4. A. E. Karchevskaya, Y. M. Poluektov, and V. A. Korolishin, "Understanding Intervertebral Disc Degeneration: Background Factors and the Role of Initial Injury," *Biomedicines* 11, no. 10 (2023): 2714, https://doi.org/10.3390/biomedicines11102714.

5. L. E. Lisiewski, H. E. Jacobsen, D. C. M. Viola, H. M. Kenawy, D. N. Kiridly, and N. O. Chahine, "Intradiscal Inflammatory Stimulation Induces Spinal Pain Behavior and Intervertebral Disc Degeneration In Vivo," *Faseb Journal* 38, no. 1 (2024): e23364, https://doi.org/10.1096/fj.202300227R.

6. A. Samanta, T. Lufkin, and P. Kraus, "Intervertebral Disc Degeneration-Current Therapeutic Options and Challenges," *Frontiers in Public Health* 11 (2023): 1156749, https://doi.org/10.3389/fpubh.2023.1156749.

7. W. Liu, Z. Ma, Y. Wang, and J. Yang, "Multiple Nano-Drug Delivery Systems for Intervertebral Disc Degeneration: Current Status and Future Perspectives," *Bioactive Materials* 23 (2023): 274–299.

8. D. Zheng, W. Chen, T. Chen, et al., "Hydrogen Ion Capturing Hydrogel Microspheres for Reversing Inflammaging," *Advanced Materials* 36, no. 5 (2024): e2306105, https://doi.org/10.1002/adma.202306105.

9. C. Liu, L. Fan, M. Guan, et al., "A Redox Homeostasis Modulatory Hydrogel With GLRX3(+) Extracellular Vesicles Attenuates Disc Degeneration by Suppressing Nucleus Pulposus Cell Senescence," *ACS Nano* 17, no. 14 (2023): 13441–13460, https://doi.org/10.1021/acsnano.3c01713.

10. Y. Li, K. Zhang, X. Ai, et al., "A Biomimetic Peptide Functions as Specific Extracellular Matrix for Quiescence of Stem Cells Against Intervertebral Disc Degeneration," *Small* 19, no. 44 (2023): e2300578, https://doi.org/10.1002/smll.202300578.

11. L. Zhou, F. Cai, H. Zhu, et al., "Immune-Defensive Microspheres Promote Regeneration of the Nucleus Pulposus by Targeted Entrapment of the Inflammatory Cascade During Intervertebral Disc Degeneration," *Bioactive Materials* 37 (2024): 132–152.

12. K. Nguyen, H. Y. Pan, K. Haworth, et al., "Multiple-Exposure Drug Release From Stable Nanodroplets by High-Intensity Focused Ultrasound for a Potential Degenerative Disc Disease Treatment," *Ultrasound in Medicine & Biology* 45, no. 1 (2019): 160–169, https://doi.org/10.1016/j.ultrasmedbio.2018.09.014.

13. Y. Ding, H. Wang, Y. Wang, et al., "Co-Delivery of Luteolin and TGF-β1 Plasmids With ROS-Responsive Virus-Inspired Nanoparticles for Microenvironment Regulation and Chemo-Gene Therapy of Intervertebral Disc Degeneration," *Nano Research* 15, no. 9 (2022): 8214–8227, https://doi.org/10.1007/s12274-022-4285-7.

14. H. Wang, Y. Ding, W. Zhang, et al., "Oxymatrine Liposomes for Intervertebral Disc Treatment: Formulation, In Vitro and Vivo Assessments," *Drug Design, Development and Therapy* 14 (2020): 921–931, https://doi.org/10.2147/DDDT.S242493.

15. F. Colella, J. P. Garcia, M. Sorbona, et al., "Drug Delivery in Intervertebral Disc Degeneration and Osteoarthritis: Selecting the Optimal Platform for the Delivery of Disease-Modifying Agents," *Journal Control Release* 328 (2020): 985–999, https://doi.org/10.1016/j.jconrel.2020.08.041.

16. L. Xiao, R. Huang, Y. Zhang, et al., "A New Formyl Peptide Receptor-1 Antagonist Conjugated Fullerene Nanoparticle for Targeted Treatment of Degenerative Disc Diseases," *ACS Applied Materials & Interfaces* 11, no. 42 (2019): 38405–38416, https://doi.org/10.1021/acsami.9b11783.

17. L. Frapin, J. Clouet, V. Delplace, M. Fusellier, J. Guicheux, and C. Le Visage, "Lessons Learned From Intervertebral Disc Pathophysiology to Guide Rational Design of Sequential Delivery Systems for Therapeutic Biological Factors," *Advanced Drug Delivery Reviews* 149–150 (2019): 49–71, https://doi.org/10.1016/j.addr.2019.08.007.

18. B. Zhang, H. Pan, Z. Chen, T. Yin, M. Zheng, and L. Cai, "Twin-Bioengine Self-Adaptive Micro/Nanorobots Using Enzyme Actuation and Macrophage Relay for Gastrointestinal Inflammation Therapy," *Science Advances* 9, no. 8 (2023): eadc8978, https://doi.org/10.1126/sciadv.adc8978.

19. G. Ma, F. Li, X. Wang, et al., "A Bionic Yeast Tumor Vaccine Using the Co-Loading Strategy to Prevent Post-Operative Tumor Recurrence," *ACS Nano* 17, no. 21 (2023): 21394–21410, https://doi.org/10.1021/acsnano.3c06115.

20. X. Zhou, X. Zhang, S. Han, et al., "Yeast Microcapsule-Mediated Targeted Delivery of Diverse Nanoparticles for Imaging and Therapy via the Oral Route," *Nano Letters* 17, no. 2 (2017): 1056–1064, https://doi.org/10.1021/acs.nanolett.6b04523.

21. L. Bai, J. Li, G. Li, D. Zhou, J. Su, and C. Liu, "Skeletal Interoception and Prospective Application in Biomaterials for Bone Regeneration," *Bone Research* 13, no. 1 (2025): 1, https://doi.org/10.1038/s41413-024-00378-w.

22. S. Jia, H. Liu, T. Yang, et al., "Single-Cell Sequencing Reveals Cellular Heterogeneity of Nucleus Pulposus in Intervertebral Disc Degeneration," *Scientific Reports* 14, no. 1 (2024): 27245, https://doi.org/10.1038/s41598-024-78675-x.

23. J. Koroth, E. O. Buko, R. Abbott, et al., "Macrophages and Intervertebral Disc Degeneration," *International Journal of Molecular Sciences* 24, no. 2 (2023): 1367, https://doi.org/10.3390/ijms24021367.

24. Y. Zhang, Q. Shen, L. Leng, et al., "Incipient Diploidization of the Medicinal Plant Perilla Within 10,000 Years," *Nature Communications* 12, no. 1 (2021): 5508, https://doi.org/10.1038/s41467-021-25681-6.

25. D. Cyranoski, "China is Promoting Coronavirus Treatments Based on Unproven Traditional Medicines," *Nature* (2020), https://doi.org/10.1038/d41586-020-01284-x.

26. S. Singh, "From Exotic Spice to Modern Drug?," *Cell* 130, no. 5 (2007): 765–768, https://doi.org/10.1016/j.cell.2007.08.024.

27. X. Gan, Z. Shu, X. Wang, et al., "Network Medicine Framework Reveals Generic Herb-Symptom Effectiveness of Traditional Chinese Medicine," *Science Advances* 9, no. 43 (2023): eadh0215, https://doi.org/10.1126/sciadv.adh0215.

28. R. Zhang, L. Han, W. Lin, et al., "Mechanisms of NLRP3 Inflammasome in Rheumatoid Arthritis and Osteoarthritis and the Effects of Traditional Chinese Medicine," *Journal of Ethnopharmacology* 321 (2024): 117432, https://doi.org/10.1016/j.jep.2023.117432.

29. Y. Wang, H. Cheng, T. Wang, K. Zhang, Y. Zhang, and X. Kang, "Oxidative Stress in Intervertebral Disc Degeneration: Molecular Mechanisms,

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Pathogenesis and Treatment," *Cell Proliferation* 56, no. 9 (2023): e13448, https://doi.org/10.1111/cpr.13448.

30. T. W. Corson and C. M. Crews, "Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials," *Cell* 130, no. 5 (2007): 769–774, https://doi.org/10.1016/j.cell.2007.08.021.

31. X. Yin, S. Lin, Y. Xiong, P. Zhang, and X. Mei, "Biomimetic Nanoplatform With Anti-Inflammation and Neuroprotective Effects for Repairing Spinal Cord Injury in Mice," *Mater Today Bio* 23 (2023): 100836, https://doi.org/10.1016/j.mtbio.2023.100836.

32. Y. Wang, F. Zhao, X. Wang, et al., "Targeted Liposomes for Macrophages-Mediated Pulmonary Fibrosis Therapy," *Drug Delivery and Translational Research* 14 (2024): 2356–2369, https://doi.org/10.1007/s13346-023-01508-3.

33. X. Zheng, Y. Xing, K. Sun, H. Jin, W. Zhao, and F. Yu, "Combination Therapy With Resveratrol and Celastrol Using Folic Acid-Functionalized Exosomes Enhances the Therapeutic Efficacy of Sepsis," *Advanced Healthcare Materials* 12, no. 29 (2023): e2301325, https://doi.org/10.1002/adhm.202301325.

34. Z. Yao, L. Nie, Y. Zhao, et al., "Salubrinal Suppresses IL-17-Induced Upregulation of MMP-13 and Extracellular Matrix Degradation through the NF-kB Pathway in Human Nucleus Pulposus Cells," *Inflammation* 39, no. 6 (2016): 1997–2007, https://doi.org/10.1007/s10753-016-0435-y.

35. W. S. Choi, G. Lee, W. H. Song, et al., "The CH25H-CYP7B1-RORalpha Axis of Cholesterol Metabolism Regulates Osteoarthritis," *Nature* 566, no. 7743 (2019): 254–258, https://doi.org/10.1038/s41586-019-0920-1.

36. M. Arra and Y. Abu-Amer, "Cross-Talk of Inflammation and Chondrocyte Intracellular Metabolism in Osteoarthritis," *Osteoarthritis and Cartilage* 31, no. 8 (2023): 1012–1021, https://doi.org/10.1016/j.joca.2023.04.003.

37. W. Li, Z. Ding, H. Zhang, et al., "The Roles of Blood Lipid-Metabolism Genes in Immune Infiltration Could Promote the Development of IDD," *Frontiers in Cell and Developmental Biology* 10 (2022): 844395, https://doi.org/10.3389/fcell.2022.844395.

38. Q. Yang, Y. Zhao, N. Li, et al., "Identification of Polyunsaturated Fatty Acids as Potential Biomarkers of Osteoarthritis After Sodium Hyaluronate and Mesenchymal Stem Cell Treatment Through Metabolomics," *Frontiers in Pharmacology* 14 (2023): 1224239, https://doi.org/10.3389/fphar.2023.1224239.

39. L. C. Costa-Beber and F. Guma, "The Macrophage Senescence Hypothesis: The Role of Poor Heat Shock Response in Pulmonary Inflammation and Endothelial Dysfunction Following Chronic Exposure to Air Pollution," *Inflammation Research* 71, no. 12 (2022): 1433–1448, https://doi.org/10.1007/s00011-022-01647-2.

40. T. Behl, I. Kaur, H. Goel, and A. Kotwani, "Implications of the Endogenous PPAR-Gamma Ligand, 15-Deoxy-Delta-12, 14-Prostaglandin J2, in Diabetic Retinopathy," *Life Sciences* 153 (2016): 93–99, https://doi.org/10.1016/j.lfs.2016.03.054.

41. P. Thornton, V. Reader, Z. Digby, et al., "Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796," *Journal of Pharmacology and Experimental Therapeutics* 388, no. 3 (2024): 813–826, https://doi.org/10.1124/jpet.123.002013.

42. M. Yan, Z. Song, H. Kou, et al., "New Progress in Basic Research of Macrophages in the Pathogenesis and Treatment of Low Back Pain," *Frontiers in Cell and Developmental Biology* 10 (2022): 866857, https://doi.org/10.3389/fcell.2022.866857.

43. Z. Yuan, D. Jiang, M. Yang, et al., "Emerging Roles of Macrophage Polarization in Osteoarthritis: Mechanisms and Therapeutic Strategies," *Orthopedic Surgery* 16, no. 3 (2024): 532–550, https://doi.org/10.1111/os.13993.

44. T. Xie, Q. Xu, H. Wan, et al., "Lipopolysaccharide Promotes Lung Fibroblast Proliferation Through Autophagy Inhibition via Activation of the PI3K-Akt-mTOR Pathway," *Laboratory Investigation* 99, no. 5 (2019): 625–633, https://doi.org/10.1038/s41374-018-0160-2.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.

Supporting Information File 1: exp270122-sup-0001-SuppMat.docx.

27662098, 2026, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/EXP.20250061 by CochraneChina, Wiley Online Library on [08/06/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License